A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single-ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and Pharmacokinetics (Part A) and an Open-label Assessment of the Effect of Food on the Pharmacokinetics (Part B) of Orally Administered AZD8418
Latest Information Update: 25 Jan 2016
At a glance
- Drugs AZD 8418 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 16 May 2014 New trial record